Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
View ORCID ProfileJoseph J. Sabatino Jr., Kristen Mittl, View ORCID ProfileWilliam Rowles, Kira Mcpolin, View ORCID ProfileJayant V. Rajan, View ORCID ProfileColin R. Zamecnik, View ORCID ProfileRavi Dandekar, View ORCID ProfileBonny D. Alvarenga, View ORCID ProfileRita P. Loudermilk, Chloe Gerungan, View ORCID ProfileCollin M. Spencer, Sharon A. Sagan, View ORCID ProfileDanillo G. Augusto, View ORCID ProfileJessa Alexander, Jill A. Hollenbach, View ORCID ProfileMichael R. Wilson, View ORCID ProfileScott S. Zamvil, View ORCID ProfileRiley Bove
doi: https://doi.org/10.1101/2021.09.10.21262933
Joseph J. Sabatino Jr.
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Kristen Mittl
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
William Rowles
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Kira Mcpolin
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Jayant V. Rajan
2Division of Experimental Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA
Colin R. Zamecnik
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Ravi Dandekar
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Bonny D. Alvarenga
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Rita P. Loudermilk
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Chloe Gerungan
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Collin M. Spencer
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Sharon A. Sagan
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Danillo G. Augusto
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
4Programa de Pós-Graduação em Genética, Universidade Federal do Paraná, Curitiba, Brazil
Jessa Alexander
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Jill A. Hollenbach
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
3Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
Michael R. Wilson
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Scott S. Zamvil
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Riley Bove
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Data Availability
All data are available in the main text or the supplementary materials. Raw data are available from the authors upon request.
Posted September 20, 2021.
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
Joseph J. Sabatino Jr., Kristen Mittl, William Rowles, Kira Mcpolin, Jayant V. Rajan, Colin R. Zamecnik, Ravi Dandekar, Bonny D. Alvarenga, Rita P. Loudermilk, Chloe Gerungan, Collin M. Spencer, Sharon A. Sagan, Danillo G. Augusto, Jessa Alexander, Jill A. Hollenbach, Michael R. Wilson, Scott S. Zamvil, Riley Bove
medRxiv 2021.09.10.21262933; doi: https://doi.org/10.1101/2021.09.10.21262933
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
Joseph J. Sabatino Jr., Kristen Mittl, William Rowles, Kira Mcpolin, Jayant V. Rajan, Colin R. Zamecnik, Ravi Dandekar, Bonny D. Alvarenga, Rita P. Loudermilk, Chloe Gerungan, Collin M. Spencer, Sharon A. Sagan, Danillo G. Augusto, Jessa Alexander, Jill A. Hollenbach, Michael R. Wilson, Scott S. Zamvil, Riley Bove
medRxiv 2021.09.10.21262933; doi: https://doi.org/10.1101/2021.09.10.21262933
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)